N/A N=1,171 Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY
Myopia · Hyperopia
Primary: Incidence of Adverse Events — 2; 0; 8; 3 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 Effects of Aerobic Exercise in Parkinson's Disease
Parkinson Disease
Primary: Change in Aerobic Fitness — 1.56 ml/min/kg — p=<0.001
N/A N=372 Enhancing Caregiver Support for Heart Failure Patients: the CarePartner Study
Heart Failure, Congestive
Primary: Heart Failure-specific Quality of Life — 37.0; 38.6 units on a scale — p=.975
Phase 2 N=210 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable · Previously Treated Myelodysplastic Syndrome · Refractory Chronic Lymphocytic Leukemia
Primary: Number of Participants With Grades II-IV Acute GVHD — 44; 34; 32 Participants — p=0.09
Phase 3 N=404 A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD
Pulmonary Disease, Chronic Obstructive
Primary: Adjusted Mean Endurance Time During Constant Work Rate Cycle Ergometry (CWRCE) After 12 Weeks — 463.63; 503.64; 527.51 seconds — p=0.0209
N/A N=36 Fast Track Appendectomy for Suppurative Appendicitis
Suppurative Appendicitis
Primary: Post Operative Length of Stay — 8.2; 23.4 Hours
Phase 3 N=295 Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Inspiratory Capacity at Rest Before Constant Work Rate Cycle Ergometry to Symptom Limitation at 75% Wcap — 2.440; 2.566; 2.571; 2.658 Litres — p=<0.0001
N/A N=118 Pharmacosurveillance Data Repository of Patients With and Without History of Anaphylactic Reactions Subsequent to Xolair Dosing
Allergic Asthma
Primary: Number of Participants With Clinical Signs and Symptoms of Adjudicated Anaphylaxis Events - Case Participants — 24; 2; 1; 1 participants
Phase 3 N=152 Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV
Hepatitis C
Primary: Percentage of Treatment-Naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) Target Detected (TD) or Target Not Detected (TND) — 90.1…
Phase 3 N=279 Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)
HIV Infections · Acquired Immunodeficiency Syndrome · Cytomegalovirus Retinitis
Primary: Morbidity — 88; 93; 93 participants
Phase 2 N=110 S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: The Percentage of Patients With Grade 4 (i.e. Life-threatening) Hemorrhage Toxicities Related to Protocol Treatment. — 2 percentage of participants
N/A N=26 Zenith® Dissection Endovascular System
Aortic Dissection
Primary: Number of Patients With Major Complications — 2; 4; 2; 3 participants
Phase 3 N=42 A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome
Short Bowel Syndrome
Primary: Percent Change in Parenteral Support [Parenteral Nutrition (PN)/Intravenous (IV)] Volume at Week 12 — 7.38; -9.95; -37.34; -39.11 percent change
N/A N=26 ReShape Intragastric Balloon for the Treatment of Obesity
Obesity
Primary: Total Weight Loss — -9.4 kg
Phase 2 N=95 A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
Breast Cancer
Primary: Cohorts 1 and 2: Percentage of Participants With a Confirmed Best Overall Response of Complete Response (CR) or Partial Response (PR) According to Response Evaluation…